Fixed-dose combinations in the therapy of type 2 diabetes mellitus: the way to achieving good glycemic control


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents an overview of modern approaches to the treatment of type 2 diabetes mellitus (DM2). The algorithm for the choice of hypoglycemic therapy according to the Russian Algorithm of specialized care for diabetic patients is discussed in detail. It is noted that according to the accumulated modern clinical experience, hypoglicemic monotherapy is usually effective in the first few years of the disease, but it is necessary to use combinations of various hypoglycemic agents in order to achieve and maintain the target blood glucose levels in most DM2 cases. It was concluded that modern fixed-dose combinations of hypoglycemic agents are an integral part of the DM2 pharmacotherapy.

Full Text

Restricted Access

About the authors

E. V Biryukova

FSBEI HE MGMSU n.a. A.I. Evdokimov of RMH

Email: lena@obsudim.ru
MD, Prof., Director of Teaching at the Department of . Endocrinology and Diabetology

References

  1. Dedov I.I., Shestakova M.V., Benedetti M.M., Simon D., Pakhomov I., Galstyan G. Prevalence of Type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res. Clin. Pract. 2016;115:90-5.
  2. Marln-Pehalver J.J., Martln-Timon I., Sevillano-Collantes C., Del Cahizo-Gomez FJ. Update on the treatment of type 2 diabetes mellitus. World J. Diabetes. 2016;7(17):354-95.
  3. Massi-Benedetti M. The Cost of Diabetes in Europe - Type II: the CODE-2 Study. Diabetolody 2002;45(7):S1-4.
  4. Echouffo-Tcheugui J.B., Kengne A.P. On the importance of global cardiovascular risk assessment in people with type 2 diabetes. Prim Care Diabetes. 2013;7:95-102.
  5. Papatheodorou K., Papanas N., Banach M., Papazoglou D., Edmonds M. Complications of Diabetes 2016. J. Diabetes Res. 2016;2016:6989453.
  6. Kannel W.B., Mc Gree D.L. Diabetes and cardiovascular disease: the Frammingam study. JAMA. 1979;241:2035-38.
  7. Ryden L.J., Grant P.D., Anker S., Berne C., Cosentino F., Danchin N., Deaton C., Escaned J., Hammes H., Huikuri H., Marre M., Marx N., Mellbin L., Ostergren J., Patrono C., Seferovic P., Sousa Uva M., Taskinen M., Tendera M., Tuomilehto J., Valensi P., Luis Zamorano J. Рекомендации по диабету, предиабету и сердечно-сосудистым заболеваниям. EASD/ ESC. Российский кардиологический журнал. 2014;(3):7-61.
  8. Алгоритмы специализированной медицинской помощи больных сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, 8-й выпуск. М., 2017.
  9. Bolen S., Feldman L., Vassy J., Wilson L., Yeh H.C., Marinopoulos S., Wiley C., Selvin E., Wilson R., Bass E.B., Brancati F.L.Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann. Intern. Med. 2007;147(6):386-99.
  10. Turner R.C., Cull C.A., Frighi V., Holman R.R. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-12.
  11. Brown J.B., Conner C., Nichols G.A. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33:501-6.
  12. Moses R.G. Combination therapy for patients with type 2 diabetes: repaglinide in combination with metformin. Expert Rev. Endocrinol. Metab. 2010;5(3):331-42.
  13. Schernthaner G. Fixed-dose combination therapies in the management of hyperglycaemia in type 2 diabetes: an opportunity to improve adherence and patient care. Diabet. Med. 2010;27(7):739-43.
  14. Tosi F., Muggeo M., Brun E., Spiazzi G., Perobelli L., Zanolin E., Gori M., Coppini A., Moghetti P. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism. 2003;52(7):862-67.
  15. Cheong C.,Barner J.C.,Lawson K.A.,Johnsrud M.T. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clinical Therapeutics. 2008;30:10:1893-1907.
  16. Rozenfeld Y., Hunt J.S., Plauschinat C., Wong K.S. Oral antidiabetic medication adherence and glycemic control in managed care. Am. J. Manag. Care 2008;14:71-5.
  17. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218-24.
  18. Ho PM., Rumsfeld J.S., MasoudiF.A.,McClure D.L., Plomon don M.E., Steiner J.F., Magid D.J. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch. Intern. Med. 2006;166: 1836-41.
  19. Hermann L.S., Schersten B., Bitzen P.O., Kjellström T., Lindgärde F., Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care. 1994;17:1100.
  20. Azoulay A., Schneider-Lindner V., Dell'Aniell S. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Pharmacoepidemiol. Drug Safety. 2010;19(4):335-42.
  21. Анциферов М.Б., Майоров А.Ю., Дорофеева Л.Г. Опыт использования комбинированного сахароснижающего препарата Глибомет (глибенкламид+метформин) в практике лечения сахарного диабета 2 типа. Фарматека. 2006;3:68-72.
  22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes. (UKPDS 33). Lancet. 1998;352:837-53.
  23. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854.
  24. Davidson M.B., Peters A.L. An overview of metformin in the treatment of type 2 diabetes mellitus. Am. J. Med. 1997;102:99-110.
  25. Kahn S.E. The relative contributions of insulin resistance and ß-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003:46(1):3-19.
  26. Philippe J., Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents? Int. J. Clin. Pract. 2009;63(2):321-32.
  27. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 1999;131:281-303.
  28. McFarlane S.I., Banerij M., Sowers J.R. Insulin resistance and cardiovascular disease. J. Clin. Endocrinol. Metab. 2001;86:713-18.
  29. Scarpello J.H.B. Improving survival with metformin: the evidence base today. Diabetes Metab. 2003;29:6S36-6S43.
  30. Eurich D.T., McAlister F.A., Blackburn D.F., Majumdar S.R., Tsuyuki R.T, VarneyJ.,JohnsonJ.A. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007;335(7618): 497-507.
  31. Kirpichnikov D., McFarlane S.I., Sowers J.R, Metformin: An Update. Ann. Intern. Med. 2002;137:25-33.
  32. He L., Sabet A., Djedjos S., Miller R., Sun X., Hussain M.A., Radovick S., Wondisford F.E. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009; 137(4):635-46.
  33. Jeppesen J., Zhou M.Y, Chen Y.D., Reaven G.M. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 1994;17:1093.
  34. Golay A. Metformin and body weight. Inter. L Obesirt. 2008;32:61-72.
  35. Mannucci E., Ognibene A., Cremasco F, Bardini G., Mencucci A., Pierazzuoli E., Ciani S., Fanelli A., Messeri G, Rotella C.M. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001;24(3):489-94.
  36. Gagnon J., Sheppard E., Anin Y.I. Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diabet., Obes. Metab. 2012; 153(8):3646-356.
  37. Katakam R.V., Ujhelyi M.R., Hoenig M., Miller A.W. Metformin improves vascular function in insulin-resistant rats. Hypertension. 2000;35:108-112.
  38. Arunachalam G., Samuel S., Marei I., Ding H., Triggle C. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br. J. Pharmacol. 2014; 171:523-35.
  39. Triggle C.D., Ding H. Cardiovascular impact of drugs used in the treatment of diabetes. Ther. Adv. Chronic Dis. 2014;5(6):245-68.
  40. Abbasi F., Chu J.W., McLaughlin T., Lamendola C., Leary E.T., Reaven G.M. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism. 2004;53(2):159-64.
  41. Donnan PT., Macdonald T. M., Morris A.D. Adherence to prescribed oral hypoglycaemic medication in population of patients with type 2 diabetes: a retrospective cohort study. Diabet. Med. 2002;19:279-84.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies